Phaseline

Companies › Sichuan Jishengtang Pharmaceutical

Sichuan Jishengtang Pharmaceutical: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 3; Neurology, Psychiatry; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Wujia Yizhi granules
Traditional Chinese medicine formula for treatment of mild-to-moderate Alzheimer's dementi
–Phase 3Alzheimer's DementiaDec 2026
Shugan Jieyu Capsules
Herbal formulation
–Phase 3Generalized Anxiety Disorder–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05772104Shugan Jieyu CapsulesPhase 3Generalized Anxiety DisorderPsychiatryFeb 2025
NCT06534723Wujia Yizhi granulesPhase 3Alzheimer's DementiaNeurologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Impax Laboratories Intra-Cellular Therapies Rapport Therapeutics Lipocine Xenon Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.